A Phase 1b, Randomised, Controlled, Assessor-blinded Proof of Principle Trial to Assess Safety, Tolerability and Pharmacodynamics Effects of Microarray Patches Containing Calcipotriol/Betamethasone Dipropionate in Descaled Skin of Adults With Chronic Plaque Psoriasis Over a 21-day Treatment Period
Overview
- Phase
- Phase 1
- Intervention
- Microarray patch A
- Conditions
- Psoriasis Vulgaris
- Sponsor
- LEO Pharma
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- Overall number of treatment-emergent adverse events.
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
To assess safety, tolerability and pharmacodynamics effect of treatment with microarray patches containing calcipotriol and betamethasone dipropionate.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects with psoriasis vulgaris in a chronic stable phase and mild to moderate plaque(s) covering a sufficient area to allocate 4 test fields on up to 3 comparable plaques.
- •Men and women aged 18-70 years (inclusive).
- •Sufficient target lesion(s) must be present on the trunk or extremities (excluding palms/soles); psoriatic lesions on the knees or elbows are not to be used as target lesions.
- •Plaques to be treated should have a comparable thickness of the EPB of the inflammatory infiltrate of at least 200 μm.
- •Plaques to be treated should have no more than a 2-fold difference in infiltrate thickness between the test fields.
- •Physical examination of skin must be without abnormal, clinical significant findings other than psoriasis vulgaris unless the investigator considers an abnormality to be irrelevant to the trial outcome.
Exclusion Criteria
- •Other skin disease noted on physical examination that is considered by the investigator to be relevant to the outcome of the trial.
- •Subjects with acute psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, pustular, exfoliative or inverse psoriasis.
- •History of psoriasis that was unresponsive or poorly responsive to topical treatments.
- •Topical antipsoriatics are not permitted on the same body area as plaques to be treated during the 4 weeks before first treatment and during the trial.
- •Systemic treatment with antipsoriatics e.g. corticosteroids, cytostatics, retinoids, dimethylfumarate, apremilast in the 3 months before first treatment and during the trial.
- •Systemic treatment with biological treatments: rituximab within 12 months, ustekinumab or secukinumab within 6 months before first treatment and during the trial.
- •Systemic treatment with biological treatments within 3 months before first treatment and during the trial.
- •Systemic treatment with any other biological treatments within the period of 5 half-lives of the biological before first treatment and during the trial.
- •UV-therapy or extensive exposure to UV radiation or sunlight within 4 weeks before first treatment and during the trial.
- •Treatment with concomitant medication that may affect and provoke or aggravate psoriasis, unless on a stable dose for 3 months before trial medication initiation.
Arms & Interventions
Microarray patch A
21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use
Intervention: Microarray patch A
Microarray patch B
21 day treatment, 3 times weekly, 9 applications in total, transdermal patch for cutaneous use
Intervention: Microarray patch B
Vehicle
21 day treatment, once weekly, 3 applications in total, transdermal patch for cutaneous use, no active substance
Intervention: Placebo
Daivobet
21 day treatment, paused on day 7, day 14 and day 21, Cutaneous use
Intervention: Daivobet
Outcomes
Primary Outcomes
Overall number of treatment-emergent adverse events.
Time Frame: First IMP application up to trial end (Day 50)
Number of treatment-emergent application site reactions, by treatment
Time Frame: First IMP application up to trial end (Day 50)
Change from baseline to Day 22 (EoT) in haematology parameters.
Time Frame: From baseline up to EoT (Day 22)
RBC, WBC, haemoglobin, haematocrit, platelets, white cell differentials; measured in SI units.
Change from baseline to Day 22 (EoT) in clinical chemistry parameters.
Time Frame: From baseline to EoT (Day 22)
Sodium, potassium, BUN, glucose, AST, ALT, gamma GT, AP, calcium, phosphate, albumin, total cholesterol, LDH, total protein, creatinine, total bilirubin; measured in SI units.
Change from baseline to Day 22 (EoT) in urinalysis parameters, single parameters only to be listed if deviation from usual urine dip test.
Time Frame: From baseline to EoT (Day 22)
E.g., leukocytes, nitrite, pH, protein, glucose, ketones, urobilinogen, bilirubin, blood/haemoglobin, measured in SI units.
Number of subjects with abnormal clinically significant findings of physical examination at Day 22 (EoT).
Time Frame: EoT (Day 22)
Evaluation of physical examination (areas skin, heart, lung, abdomen, basic neurological status, general examination of eyes, ears, nose, throat), overall evaluation, assessed by investigator as 'normal', 'abnormal not clinically significant', 'abnormal clinically significant'.
Change from baseline to Day 22 (EoT) in systolic and diastolic blood pressure.
Time Frame: From baseline to EoT (Day 22)
Measured in mmHg.
Change from baseline to Day 22 (EoT) in pulse.
Time Frame: From baseline to EoT (Day 22)
Measured in beats per minute.
Frequency counts of overall tolerability assessment of skin reactions at Day 8, Day 15, Day 22, Day 36 and Day 50.
Time Frame: From baseline up to trial end (Day 50)
(Assessment performed by an investigator using a 4-point score \['0 = very good', '1 = good', '2 = moderate', '3 = poor'\]).
Secondary Outcomes
- Change from baseline (pre-dose at Day 1) to Day 22 (EoT) in psoriatic infiltrate thickness.(EoT (Day 22))